Solid Biosciences Inc. Repayment of Long-term Debt, Long-term Lease Obligation, and Capital Security
Solid Biosciences Inc. (SLDB) reported Repayment of Long-term Debt, Long-term Lease Obligation, and Capital Security of $0 for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Financing Activities
us-gaap:RepaymentsOfLongTermDebtAndCapitalSecurities · last filed 2026-08-06
- Solid Biosciences Inc. repayment of long-term debt, long-term lease obligation, and capital security for the quarter ending 2026-06-30 was $0.00, a 100.00% decline year-over-year.
- Solid Biosciences Inc. repayment of long-term debt, long-term lease obligation, and capital security for the quarter ending 2026-03-31 was $0.00, a 100.00% decline year-over-year.
- Solid Biosciences Inc. repayment of long-term debt, long-term lease obligation, and capital security for the quarter ending 2025-12-31 was $203.00K, a 58.59% increase year-over-year.
- Solid Biosciences Inc. repayment of long-term debt, long-term lease obligation, and capital security for the quarter ending 2025-09-30 was $243.00K, a 102.50% increase year-over-year.
- Solid Biosciences Inc. repayment of long-term debt, long-term lease obligation, and capital security for fiscal 2025 was $723.00K, a 52.85% increase from fiscal 2024.
- Solid Biosciences Inc. repayment of long-term debt, long-term lease obligation, and capital security for fiscal 2024 was $473.00K.
| Period end | Repayment of Long-term Debt, Long-term Lease Obligation, and Capital Security 3 month | Repayment of Long-term Debt, Long-term Lease Obligation, and Capital Security 6 month | Repayment of Long-term Debt, Long-term Lease Obligation, and Capital Security 9 month | Repayment of Long-term Debt, Long-term Lease Obligation, and Capital Security 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $0.00 10-Q · filed 2026-08-06 | $203.00K derived: sum of 3 quarters · filed 2026-08-06 | $446.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $0.00 10-Q · filed 2026-05-12 | $203.00K derived: sum of 2 quarters · filed 2026-05-12 | $446.00K derived: sum of 3 quarters · filed 2026-05-12 | $588.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $203.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $446.00K derived: sum of 2 quarters · filed 2026-03-19 | $588.00K derived: sum of 3 quarters · filed 2026-08-06 | $723.00K 10-K · filed 2026-03-19 |
| 2025-09-30 | $243.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-03 | $385.00K derived: sum of 2 quarters · filed 2026-08-06 | $520.00K 10-Q · filed 2025-11-03 | $648.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $142.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $277.00K 10-Q · filed 2026-08-06 | $405.00K derived: sum of 3 quarters · filed 2026-08-06 | $525.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $135.00K 10-Q · filed 2026-05-12 | $263.00K derived: sum of 2 quarters · filed 2026-05-12 | $383.00K derived: sum of 3 quarters · filed 2026-05-12 | $608.00K derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $128.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $248.00K derived: sum of 2 quarters · filed 2026-03-19 | $473.00K derived: sum of 3 quarters · filed 2026-03-19 | $473.00K 10-K · filed 2026-03-19 |
| 2024-09-30 | $120.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-03 | $345.00K derived: sum of 2 quarters · filed 2025-11-03 | $345.00K 10-Q · filed 2025-11-03 | |
| 2024-06-30 | $225.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $225.00K 10-Q · filed 2025-08-12 | ||
| 2024-03-31 | $0.00 10-Q · filed 2025-05-15 | |||
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $0.00 10-Q · filed 2024-11-06 | ||
| 2023-06-30 | $0.00 10-Q · filed 2024-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |